584 related articles for article (PubMed ID: 23089251)
1. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.
Anderson LJ; Wyatt KM; Henley W; Nikolaou V; Waldek S; Hughes DA; Pastores GM; Logan S
J Inherit Metab Dis; 2014 Nov; 37(6):969-78. PubMed ID: 24831586
[TBL] [Abstract][Full Text] [Related]
3. The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders.
Henley WE; Anderson LJ; Wyatt KM; Nikolaou V; Anderson R; Logan S
J Inherit Metab Dis; 2014 Nov; 37(6):939-44. PubMed ID: 24519353
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.
Anderson LJ; Henley W; Wyatt KM; Nikolaou V; Waldek S; Hughes DA; Lachmann RH; Logan S
J Inherit Metab Dis; 2014 Nov; 37(6):945-52. PubMed ID: 24906254
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
Connock M; Juarez-Garcia A; Frew E; Mans A; Dretzke J; Fry-Smith A; Moore D
Health Technol Assess; 2006 Jun; 10(20):iii-iv, ix-113. PubMed ID: 16729919
[TBL] [Abstract][Full Text] [Related]
6. [Enzyme replacement therapy of lysosomal storage diseases].
Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study.
Anderson LJ; Henley W; Wyatt KM; Nikolaou V; Hughes DA; Waldek S; Logan S
J Inherit Metab Dis; 2014 Nov; 37(6):953-60. PubMed ID: 24515873
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country's approach (England) to that of a middle-income one (Colombia).
Castro-Jaramillo HE
Rev Salud Publica (Bogota); 2012; 14(1):143-55. PubMed ID: 23250322
[TBL] [Abstract][Full Text] [Related]
9. Treating lysosomal storage disorders: What have we learnt?
Lachmann RH
J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L
Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study.
Anderson LJ; Henley W; Wyatt KM; Nikolaou V; Waldek S; Hughes DA; Pastores GM; Logan S
J Inherit Metab Dis; 2014 Nov; 37(6):961-8. PubMed ID: 24638276
[TBL] [Abstract][Full Text] [Related]
12. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
13. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.
van Dussen L; Biegstraaten M; Hollak CE; Dijkgraaf MG
Orphanet J Rare Dis; 2014 Apr; 9():51. PubMed ID: 24731506
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
17. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy for lysosomal storage diseases.
Ohashi T
Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review.
Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A
Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
